Preclinical Development – Biomolecular
2019 PharmSci 360
Deep sequencing focuses its sequencing reads on few small regions of the genome and thus achieves very sensitive detection of sub-clonal mutations. Liquid biopsy, an application of deep sequencing, has gained tremendous interests in the oncology research community. Before deep sequencing is ready for use in clinical and regulatory settings, some major uncertainties need to be addressed. The FDA-led MicroArray Quality Control (MAQC) consortium seeks to assess validity, reliability, as well as recommend sound analysis methods for deep sequencing and whole genome sequencing in its fourth project that is also named Sequencing Quality Control Phase 2 (SEQC2).